Can Low-Oxygen Conditions Improve TIL Therapy for Kidney Cancer?

Growing TILs in an environment with 5% oxygen improved efficacy of treatment, study says

Top Moffitt Research Stories of 2024

From FDA approvals to drug discovery, Moffitt led the way this past year

Moffitt Experts’ Study Aims to Improve TIL Therapy Process

Tumor-infiltrating lymphocyte therapy is FDA approved to treat melanoma.

New Immunotherapy Combination Shows Promise in Advanced Lung Cancer

Adding pembrolizumab to TIL therapy shrunk tumors in almost half of trial patients

Moffitt Experts Share Discoveries Driving Innovation in Cancer Immunotherapy

The Society for Immunotherapy of Cancer brings together industry leaders to highlight new research and clinical applications in immunotherapy

Moffitt Hosts Inaugural Cell Coast Conference to Spotlight Breakthroughs in Cellular Immunotherapy

Experts discuss the latest advances in CAR T, TIL and TCR therapies

What Is Immunotherapy?

Harnessing the immune system to attack cancer gives patients new treatment options

Next Generation of TIL Therapy Being Developed for Head and Neck Cancers

Standard of care fails 80% of patients with advanced squamous cell carcinoma

Endeavor